Breaking News Instant updates and real-time market news.

AVXS

AveXis

$44.55

2.36 (5.59%)

07:42
10/06/16
10/06
07:42
10/06/16
07:42

AveXis attractive acquisition target, price target to $71 at Goldman

Goldman analyst Salveen Richter said AveXis has two approaching catalysts coming up, the AVXS-101 update in SMA Type 1 at the World Muscle Society, or WMS, on October 8, and clarity on the AVXS-101 pivotal trial design in late October/early November. The analyst expects positive WMS data and raaised his probability of success to 60% from 45%. He expects compelling motor milestone data and pivotal trial visibility to make AveXis an attractive acquisition target and raised his price target to $71 from $46 on shares and reiterated his Buy rating.

  • 06

    Nov

AVXS AveXis
$44.55

2.36 (5.59%)

08/17/16
WELS
08/17/16
UPGRADE
WELS
Outperform
AveXis upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded AveXis (AVXS) to Outperform after speaking to five experts in spinal muscular atrophy. The experts were impressed with both Ionis Pharmaceuticals (IONS)/Biogen's (BIIB) nusinersen and AveXis' gene therapy AVXS101, and suggested that likely incomplete restoration of normal neuromuscular phenotype could prompt combination use of both treatments, Birchenough tells investors in a research note. The analyst raised his price target range for AveXis shares to $56-$61 from $30-$32. The stock closed yesterday down $1.91 to $41.66.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies thinks it found baby in AveXis trial that is walking
Jefferies analyst Biren Amin believes a video posted online of a baby walking has a "strong likelihood" of being a patient in AveXis' AVXS-101 trial. AVXS-101 is a gene therapy candidate in Phase I testing for spinal muscular atrophy. The near 20 month old's achievement to walk "is significant" given that she is a Type 1 SMA baby with 2 copy number and would not in any normal circumstance be expected to walk, Amin tells investors in a research note. The analyst points out that his finding online comes ahead of AveXis' plan to disclose patient data on motor milestones from its Phase 1 trial later this year. To reflect increased confidence in AVXS-101's prospects, Amin raised his price target for the shares to $50 from $42. The clinical-stage gene therapy company, formerly known as Biolife Cell Bank, closed Friday up 83c to $41.72.
09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.

TODAY'S FREE FLY STORIES

TGT

Target

$66.91

0.4 (0.60%)

, AZO

AutoZone

$740.85

8.1 (1.11%)

20:25
02/27/17
02/27
20:25
02/27/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TGT

Target

$66.91

0.4 (0.60%)

AZO

AutoZone

$740.85

8.1 (1.11%)

DPZ

Domino's Pizza

$185.42

-0.86 (-0.46%)

VRX

Valeant

$16.71

0.53 (3.28%)

PAH

Platform Specialty Products

$13.30

0.25 (1.92%)

ENDP

Endo

$13.29

0.14 (1.06%)

DDD

3D Systems

$16.94

0.45 (2.73%)

SEAS

SeaWorld

$18.78

0.16 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 02

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

CSCO

Cisco

$34.26

-0.06 (-0.17%)

20:04
02/27/17
02/27
20:04
02/27/17
20:04
Hot Stocks
Cisco says signs three-year services agreement with Saudi Telecom »

At Mobile World Congress,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 03

    Mar

YHOO

Yahoo

$45.71

0.16 (0.35%)

, VZ

Verizon

$49.94

-0.66 (-1.30%)

20:01
02/27/17
02/27
20:01
02/27/17
20:01
Hot Stocks
Yahoo responds to Senate information request on cybersecurity breaches »

Responding to a February…

YHOO

Yahoo

$45.71

0.16 (0.35%)

VZ

Verizon

$49.94

-0.66 (-1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:38
02/27/17
02/27
19:38
02/27/17
19:38
Hot Stocks
Priceline: 'Solid start' to Q1, shift of Easter into Q2 to pressure some metrics »

During the company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

ROYT

Pacific Coast Oil

$1.94

0.02 (1.04%)

19:33
02/27/17
02/27
19:33
02/27/17
19:33
Downgrade
Pacific Coast Oil rating change  »

Pacific Coast Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAT

Arctic Cat

$18.49

-0.01 (-0.05%)

, BDRBF

Bombardier

$1.81

-0.03 (-1.63%)

19:28
02/27/17
02/27
19:28
02/27/17
19:28
Hot Stocks
Court rules in favor of Arctic Cat in Bombardier patent litigation »

Arctic Cat (ACAT)…

ACAT

Arctic Cat

$18.49

-0.01 (-0.05%)

BDRBF

Bombardier

$1.81

-0.03 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:17
02/27/17
02/27
19:17
02/27/17
19:17
Hot Stocks
Priceline CFO: 'Hopeful' on promised Trump tax reform »

During the company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:16
02/27/17
02/27
19:16
02/27/17
19:16
Hot Stocks
Priceline says board approved new $2B buyback authorization »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

VTVT

vTv Therapeutics

$6.14

0.45 (7.91%)

19:09
02/27/17
02/27
19:09
02/27/17
19:09
Hot Stocks
vTv Therapeutics sees reporting topline data from STEADFAST Part A in early 2018 »

Says STEADFAST Part B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:55
02/27/17
02/27
18:55
02/27/17
18:55
Earnings
AAC Holdings sees FY17 adjusted EPS 50c-58c, consensus 72c »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CSX

CSX

$48.71

0.23 (0.47%)

18:54
02/27/17
02/27
18:54
02/27/17
18:54
Hot Stocks
CSX sees at least $160M charge from 'management streamlining' plan »

CSX disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$76.45

0.15 (0.20%)

18:54
02/27/17
02/27
18:54
02/27/17
18:54
Hot Stocks
Iowa American Water rate adjustment approved by IUB »

Following a 10-month…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:53
02/27/17
02/27
18:53
02/27/17
18:53
Hot Stocks
AAC Holdings sees over $8M in savings in 2017 from workforce reduction »

Management said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MORN

Morningstar

$81.62

-0.1 (-0.12%)

18:52
02/27/17
02/27
18:52
02/27/17
18:52
Hot Stocks
Morningstar CFO Stephane Biehler to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$248.60

3.55 (1.45%)

18:51
02/27/17
02/27
18:51
02/27/17
18:51
Hot Stocks
Northrop Grumman appoints Pamiljans as aerospace systems president »

The board of Northrop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:51
02/27/17
02/27
18:51
02/27/17
18:51
Earnings
AAC Holdings reports Q4 adjusted EPS 15c, consensus 15c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MS

Morgan Stanley

$45.84

0.31 (0.68%)

18:48
02/27/17
02/27
18:48
02/27/17
18:48
Hot Stocks
Morgan Stanley discloses erroneous client tax reporting, says in talks with IRS »

Morgan Stanley disclosed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

MS

Morgan Stanley

$45.84

0.31 (0.68%)

, BK

BNY Mellon

$47.11

0.02 (0.04%)

18:47
02/27/17
02/27
18:47
02/27/17
18:47
Hot Stocks
Morgan Stanley says reached settlement in New York Mellon dispute »

Morgan Stanley (MS)…

MS

Morgan Stanley

$45.84

0.31 (0.68%)

BK

BNY Mellon

$47.11

0.02 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

OLN

Olin Corp.

$30.90

0.1 (0.32%)

18:41
02/27/17
02/27
18:41
02/27/17
18:41
Hot Stocks
Olin Corp. chairman Joseph Rupp to retire »

Olin Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 01

    Mar

  • 14

    Mar

WHLR

Wheeler REIT

$1.83

0.06 (3.39%)

18:35
02/27/17
02/27
18:35
02/27/17
18:35
Hot Stocks
Wheeler REIT revises dividend payment schedule »

Effective April 1, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

, FCH

Felcor Lodging

$7.33

0.25 (3.53%)

18:34
02/27/17
02/27
18:34
02/27/17
18:34
Hot Stocks
Ashford Hospitality: FelCor statements on proposal 'misguided and misleading' »

Ashford Hospitality Trust…

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

FCH

Felcor Lodging

$7.33

0.25 (3.53%)

AINC

Ashford

$56.72

-0.28 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

, FCH

Felcor Lodging

$7.33

0.25 (3.53%)

18:28
02/27/17
02/27
18:28
02/27/17
18:28
Hot Stocks
Ashford Hospitality Trust acknowledges Land and Buildings endorsement »

Ashford Hospitality Trust…

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

FCH

Felcor Lodging

$7.33

0.25 (3.53%)

AINC

Ashford

$56.72

-0.28 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHLR

Wheeler REIT

$1.83

0.06 (3.39%)

18:28
02/27/17
02/27
18:28
02/27/17
18:28
Hot Stocks
Wheeler REIT announces 1-for-8 reverse stock split »

The Company's Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

VTVT

vTv Therapeutics

$6.14

0.45 (7.91%)

18:18
02/27/17
02/27
18:18
02/27/17
18:18
Earnings
vTv Therapeutics reports Q4 EPS (42c), consensus (44c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DKL

Delek Logistics

$31.20

0.65 (2.13%)

18:10
02/27/17
02/27
18:10
02/27/17
18:10
Hot Stocks
Delek Logistics targets 10% annual increase in distribution through 2019 »

CEO Yemin concluded,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.